On June 9, 2025, Spruce Biosciences, Inc. received confirmation that its appeal to resume trading on Nasdaq was accepted, provided it complies with a minimum bid price requirement by August 5, 2025. The company is also seeking stockholder approval for a reverse stock split at its upcoming meeting on July 22, 2025.